Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cantargia AB ( (SE:CANTA) ) has issued an announcement.
Cantargia AB has announced new preclinical data published in Cancer Discovery, demonstrating the potential of their antibody nadunolimab to counteract tumor-driven systemic immunosuppression by targeting IL1RAP. This research, led by Professor Douglas Hanahan, shows that blocking IL1RAP can overcome resistance to immune therapy in cancer models, with clinical data supporting these findings by showing a reduction in immunosuppressive cells in patients treated with nadunolimab. These insights suggest that nadunolimab could significantly enhance cancer treatment efficacy, particularly in overcoming resistance to existing therapies, thus potentially improving outcomes for patients and strengthening Cantargia’s position in the oncology field.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases, utilizing a platform centered on the IL1RAP protein, which is implicated in various cancer forms and inflammatory diseases. Their primary oncology program involves the antibody nadunolimab (CAN04), which is being clinically tested, mainly in combination with chemotherapy, targeting pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. The company also has a second development program, CAN10, aimed at treating autoimmune and inflammatory diseases.
YTD Price Performance: -2.61%
Average Trading Volume: 2,500
Technical Sentiment Signal: Buy
Current Market Cap: €36.77M
For a thorough assessment of CANTA stock, go to TipRanks’ Stock Analysis page.